News

Siolta Therapeutics Initiates Collaboration with Bio-Me to Develop Microbiome-based Prognostics for Early Identification of Allergy and Asthma

FDA Grants Fast Track Status to STMC-103H Program for Allergic Disease Prevention

Siolta Therapeutics Closes $30M Series B Financing to Support Clinical Development of Lead Program

Dr. John Martin, Former CEO/Chairperson of Gilead, Joins Siolta Therapeutics Executive Advisory Team

Siolta Therapeutics Supports the 3rd Annual Biotech Week at SFUSD

Siolta Therapeutics Joins the Microbiome Therapeutic Innovation Group (MTIG), a Coalition to Advance Microbial Therapeutics

Siolta Therapeutics is Awarded Bill & Melinda Gates Foundation Grant to Advance Microbial Product Manufacturing

BioCentury Covers Siolta Therapeutics’ Approach to Seeding the Infant Microbiome

Dr. Nikole Kimes Discusses Siolta Therapeutics at Precision Medicine World Conference 2018